HSD3B1 in C4-2B MDVR resensitized cells to Enza in FBS, CD-FBS+DHT and CD-FBS+P5 conditions as determined by a reduction in cell number and PSA secretion and/or PSA-luciferase activity in response to Enza. In the C4-2B AbiR cells, inhibition of HSD3B1 resensitized cells to treatment with Abi in FBS, CD-FBS, and CD-FBS + P5 conditions with the greatest effects seen in the FBS and CD-FBS + P5 containing media. Supplementation with P5, but not DHEA, was able to induce PSA-luciferase activity and cell growth in C4-2B AbiR cells and this could be blocked by knockdown of HSD3B1.
INTRODUCTION AND OBJECTIVES: Lysine-specific demethylase 1 (LSD1), the first-identified histone demethylase, is a novel target for prostate cancer therapy. We examined the anticancer effects of NCL1 and NCD38, selective inhibitors of LSD1 (LSD1i) that were first discovered at our university.
METHODS: Various tests using LNCaP (a hormone-sensitive prostate cancer cell line) and PCai1 (a castration-resistant prostate cancer [CRPC] cell line established in our institute), PC3 and 22Rv1 (CRPC cell line) cells were used to confirm the anticancer effects of NCL1 and NCD38. Cell viability was assessed by performing a WST assay. Invasion and migration assay were also performed to assess the status of cell invasion and cell migration. For autophagy analysis, cells were incubated with or without chloroquine (CQ) in the presence or absence of LSD1i. Subsequently, transmission electron microscopy (TEM), fluorescent immunocytochemistry, and WST assay were performed with the treated and non-treated cells. A combination index analysis was performed to assess the effects of LSD1i and CQ. Finally, the effect on xenograft tumors in CRPC mice models was measured by subcutaneously injecting castrated nude mice with PCai1 cells. Mice were injected intraperitoneally with LSD1i or the vehicle, and their subsequent growth was recorded.
RESULTS: The WST assay revealed reduced number of viable cells after LSD1i treatment. A dose-dependent induction of apoptosis by LSD1i was noted using flow cytometry. LSD1i inhibited invasion and migration. Autophagosomes were observed in the LNCaP cells treated with NCL1. The expression level of LC3-II was significantly increased in the cells treated with LSD1i and CQ. Moreover, the combination of NCL1 and CQ significantly decreased cell growth in vitro; however, it had no synergistic effect in vivo. Xenograft tumor volume was reduced in the NCL1 and NCD38-treated mice compared to the controls; no adverse effects were observed.
CONCLUSIONS: Castration-resistant prostate cancer growth was effectively suppressed with NCL1 and NCD38 both, in vitro and in vivo, without any adverse events via apoptosis regulation and autophagy, indicating the potential use of LSD1 inhibitors as therapeutic agents for prostate cancer.
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MP29-10 TRIM36, A NOVEL ANDROGEN-RESPONSIVE GENE, ENHANCES ANTI-ANDROGEN EFFICACY AGAINST PROSTATE CANCER BY INHIBITING MAPK/ERK SIGNALING PATHWAYS
Jie Li*, Chao Liang, Shangqian Wang, Bianjiang Liu, Gong Cheng, Chao Qin, Pengfei Shao, Zengjun Wang, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Hormone therapy drugs, such as bicalutamide and enzalutamide, directed against prostate cancer focus on androgen receptor (AR) signaling and are initially effective, but the disease progresses to lethality as resistance to these drugs develops. A method to prolong the drug response time and improve the drug efficacy is still unavailable. In this study, we investigated the functional analysis and androgen regulation of TRIM36 and its underlying mechanisms enhancing anti-androgen efficacy against prostate cancer (PCa).
METHODS: TRIM36 expression has been detected by mRNA microarray analysis, quantitative reverse transcription (qRT-PCR), Western blotting and Liquid chromatography-Mass Spectrum (LC-MS/ MS) in matched prostate cancer and adjacent normal tissues, and prostate cell lines RWPE-1, C4-2, LNCaP, DU145, PC3. A total of 95 cases of prostate cancer after radical prostatectomy were analysed in a tissue microarray (TMA) for TRIM36 and androgen receptor (AR) protein expression. Prostate cancer cells stably expressing and shRNAs knockdown TRIM36 were used for CCK-8 assay, clone formation assay and xenograft with or without ADT drugs. Androgen regulation was examined by ChIP, dual-luciferase reporter assay, qRT-PCR and Western blot analysis.
RESULTS: In this study, we found that 63.4% (64/95) of PCa in TMA expressed the TRIM36 protein. Interestingly, patients with negative TRIM36 expression had a shorter biochemical recurrencefree survival. TRIM36 expression was significantly associated with the Gleason score (P¼0.005), delayed prostate cancer cell cycle progression and inhibited cell proliferation in vitro and in vivo, and these effects were mediated via inhibition of the MAPK/ERK phosphorylation pathway. Remarkably, we found that rescuing the expression of TRIM36 during anti-androgen therapy could improve the drug efficacy.
CONCLUSIONS: Collectively, TRIM36 is a novel androgenresponsive gene, and it dramatically enhanced the efficacy of antiandrogen drugs against prostate cancer. None Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 THE JOURNAL OF UROLOGY â e369
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